299MO DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC)
曲妥珠单抗
医学
析因分析
肿瘤科
内科学
激素受体
癌症
乳腺癌
作者
Carlos H. Barrios,Aditya Bardia,Xin Hu,Rebecca Dent,Kan Yonemori,J-Y Pierga,Laura Biganzoli,Christelle Lévy,S-A. Im,Juntao Ke,C. Govindaraj,A. Andrzejuk-Ćwik,Giuseppe Curigliano
出处
期刊：ESMO open [Elsevier BV] 日期：2025-05-01卷期号：10: 104871-104871
PDF的下载单位、IP信息已删除
(2025-6-4)
yar
eric888
HEIKU
xiaokang123
若雨凌风
热心市民小红花
MchemG
薅住科研的头发
yx_cheng
Billy
风清扬
jyy
Xiaoxiao
Frank
sutharsons
Hayat
潇潇雨歇
小宋
Hans
bixiao
皖公网安备34019202002308
